SEC Filings

Show all

Stock Information

: (Common Stock)

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Governance

The Board of Directors of Selecta Biosciences sets high standards for the company’s employees, officers, and directors.
Implicit in this philosophy is the importance of sound corporate governance.

Featured Reports
Mar 12, 2020
May 02, 2019

Press Releases

01 Mar
Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference
WATERTOWN, Mass. , March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
24 Feb
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy
- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector - - ImmTOR shown to increase hepatic vector copy numbers and transgene mRNA expression - - Replicated findings supporting ImmTOR’s ability to block the formation of
17 Feb
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy – WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc.
16 Feb
Selecta Biosciences to Present at the SVB Leerink 10th Annual Global Healthcare Conference
WATERTOWN, Mass. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences , Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief